Search

Telomerase plays an important role in abnormal cell proliferation, metastasis, stem cell maintenance, and immortality in different types of cancer. As a result, the design of drugs targeting telomerase is of great significance for the treatment of cancer. In recent years, treatment strategies for telomerase have attracted extensive attention. However, finding an effective treatment is still more difficult. Understanding the structure, function and biological process of telomerase and their related proteins is of great help to drug development and clinical treatment. As a result, this research mainly introduces different biological detection methods of telomerase, including PCR, western blot, CCK-8 assay, sphere formation assay, immunocytochemistry and nanobiotic detection technology. By understanding the detection range, different aspects of detection, and advantages and disadvantages of several detection methods, the development of telomerase detection technology can be well understood. And it can better understand the activity and expression of telomerase, and hope to provide reference for future drug development targeting telomerase, telomerase and related proteins.

Non-small cell lung cancer (NSCLC) patients are particularly vulnerable to the Coronavirus Disease-2019 (COVID-19). Currently, no anti-NSCLC/COVID-19 treatment options are available. As ginsenoside Rg3 is beneficial to NSCLC patients and has been identified as an entry inhibitor of the virus, this study aims to explore underlying pharmacological mechanisms of ginsenoside Rg3 for the treatment of NSCLC patients with COVID-19.Based on a large-scale data mining and systemic biological analysis, this study investigated target genes, biological processes, pharmacological mechanisms, and underlying immune implications of ginsenoside Rg3 for NSCLC patients with COVID-19.An important gene set containing 26 target genes was built. Target genes with significant prognostic value were identified, including baculoviral IAP repeat containing 5 (BIRC5), carbonic anhydrase 9 (CA9), endothelin receptor type B (EDNRB), glucagon receptor (GCGR), interleukin 2 (IL2), peptidyl arginine deiminase 4 (PADI4), and solute carrier organic anion transporter family member 1B1 (SLCO1B1). The expression of target genes was significantly correlated with the infiltration level of macrophages, eosinophils, natural killer cells, and T lymphocytes. Ginsenoside Rg3 may benefit NSCLC patients with COVID-19 by regulating signaling pathways primarily involved in anti-inflammation, immunomodulation, cell cycle, cell fate, carcinogenesis, and hemodynamics.This study provided a comprehensive strategy for drug discovery in NSCLC and COVID-19 based on systemic biology approaches. Ginsenoside Rg3 may be a prospective drug for NSCLC patients with COVID-19. Future studies are needed to determine the value of ginsenoside Rg3 for NSCLC patients with COVID-19.